IL6 and breast carcinoma: This includes inhibiting TNF-α release [164,166] and IL-4 release [167] although the production of some mediators such as IL-6 in MCF7 breast cancer cells and splenocytes may be increased by kynurenic acid [168] indicating qualitative differences between tissues.